All In Biotech

Drug Trial Radar · NCT04616560

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Mar 8, 2021

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
NIH
First posted
Nov 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) that is newly diagnosed or has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them.

Conditions

  • Desmoplastic Small Round Cell Tumor
  • Osteosarcoma
  • Recurrent Desmoplastic Small Round Cell Tumor
  • Recurrent Kidney Wilms Tumor
  • Recurrent Osteosarcoma
  • Refractory Desmoplastic Small Round Cell Tumor
  • Refractory Wilms Tumor
  • Wilms Tumor

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT

  • Echocardiography TestProcedure

    Undergo echocardiography

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Trastuzumab DeruxtecanBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose and/or recommended phase 2 dose of DS-8201a in children at least 2 to less than 12 years old with recurrent or refractory Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) (Phase 1)Time frame: During the first cycle of therapy (cycle length = 21 days)
  2. Incidence of adverse events (AEs) in children at least 2 to less than 12 years old with recurrent or refractory WT or DSRCT (Phase 1)Time frame: Up to 30 days after last dose of study treatment
  3. Time to progressionTime frame: Up to 1 year

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama · Suspended

  • Children's Hospital Los Angeles

    Los Angeles, California · Recruiting

  • Children's Hospital of Orange County

    Orange, California · Suspended

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California · Recruiting

  • UCSF Medical Center-Mission Bay

    San Francisco, California · Suspended

  • Children's Hospital Colorado

    Aurora, Colorado · Suspended

  • Children's National Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida · Recruiting

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital

    Atlanta, Georgia · Recruiting

  • Lurie Children's Hospital-Chicago

    Chicago, Illinois · Suspended

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • Riley Hospital for Children

    Indianapolis, Indiana · Suspended

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • C S Mott Children's Hospital

    Ann Arbor, Michigan · Recruiting

  • University of Minnesota/Masonic Cancer Center

    Minneapolis, Minnesota · Suspended

  • Children's Mercy Hospitals and Clinics

    Kansas City, Missouri · Suspended

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • New York Medical College

    Valhalla, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania · Suspended

  • Saint Jude Children's Research Hospital

    Memphis, Tennessee · Recruiting

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee · Active not recruiting

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas · Recruiting

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

    Houston, Texas · Recruiting

  • Primary Children's Hospital

    Salt Lake City, Utah · Suspended

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.